#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	1328	16S	1529	1529	99.93	16S.l15.c17.ctg.1	1958	130.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	1654	1654	T	144	T	94	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	1328	16S	1529	1529	99.93	16S.l15.c17.ctg.1	1958	130.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1388	1388	C	173	C,A	112,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2288	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3382	127.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1609	1609	A	101	A	66	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2288	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3382	127.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2243	2243	C	135	C	86	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2288	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3382	127.2	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2869	2869	T	131	T,G	86,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2288	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3382	127.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2317	2317	A	151	A	97	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	102	folP	855	855	100.0	folP.l15.c4.ctg.1	1420	13.2	1	SNP	p	R229S	1	.	.	685	687	AGC	899	901	AGC	11;11;11	A;G;C	7;7;7	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	0	294	gyrA	2751	329	100.0	gyrA.l15.c4.ctg.1	490	19.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	0	294	gyrA	2751	2158	99.95	gyrA.l15.c4.ctg.2	2424	19.0	1	SNP	p	S91F	1	.	.	271	273	TTC	537	539	TTC	28;28;26	T;T;C	19;20;19	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	0	294	gyrA	2751	2158	99.95	gyrA.l15.c4.ctg.2	2424	19.0	1	SNP	p	G95N	0	.	.	283	285	GGC	549	551	GGC	26;26;26	G;G;C	17;18;17	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	0	294	gyrA	2751	2158	99.95	gyrA.l15.c4.ctg.2	2424	19.0	1	SNP	p	D95G	1	.	.	283	285	GGC	549	551	GGC	26;26;26	G;G;C	17;18;17	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	104	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1059	19.5	1	SNP	p	G45D	0	.	.	133	135	GGC	388	390	GGC	35;35;35	G;G;C	19;18;20	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	48	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	550	15.4	0	.	n	.	0	A197.	DEL	197	197	A	306	306	A	32	A	20	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	200	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2655	13.5	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1332	1334	GTC	18;17;17	G;T;C	11;11;11	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	200	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2655	13.5	1	SNP	p	D86N	0	.	.	256	258	GAC	438	440	GAC	5;5;5	G;A;C	4;4;4	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	200	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2655	13.5	1	SNP	p	R87I	0	.	.	259	261	CGT	441	443	CGT	6;6;5	C;G;T	5;5;4	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	200	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2655	13.5	1	SNP	p	R87W	0	.	.	259	261	CGT	441	443	CGT	6;6;5	C;G;T	5;5;4	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	200	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2655	13.5	1	SNP	p	S87R	1	.	.	259	261	CGT	441	443	CGT	6;6;5	C;G;T	5;5;4	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	200	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2655	13.5	1	SNP	p	S88P	0	.	.	262	264	TCC	444	446	TCC	5;5;5	T;C;C	4;4;4	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	190	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2790	13.0	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1372	1374	TGC	17;17;16	T;G;C	11;10;10	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	190	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2790	13.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1582	1584	GGC	9;9;9	G;G;C	8;8;8	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	238	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2097	21.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1076	1078	GCA	21;21;22	G;C;A	14;15;15	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	238	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2097	21.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1079	1081	ATC	22;22;22	A;T;C	15;15;16	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	238	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2097	21.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1091	1093	GTG	19;19;19	G;T;G	15;14;14	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	238	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2097	21.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1091	1093	GTG	19;19;19	G;T;G	15;14;14	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	238	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2097	21.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1595	1597	ACC	13;15;15	A;C;C	7;10;10	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	238	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2097	21.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1649	1651	GCG	8;8;8	G;C;G	6;6;6	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	238	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2097	21.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1649	1651	GCG	8;8;8	G;C;G	6;6;6	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	238	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2097	21.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1772	1774	GGC	6;6;6	G;G;C	4;4;3	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	238	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2097	21.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1781	1783	GGC	6;6;5	G;G;C	4;4;3	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	238	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2097	21.2	1	SNP	p	P552S	1	.	.	1654	1656	TCG	1799	1801	TCG	7;7;7	T;C;G	5;5;5	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	1	390	ponA	2397	1270	100.0	ponA.l15.c4.ctg.1	1490	22.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	134	136	CCG	14;14;14	C;C;G	7;8;8	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	1	390	ponA	2397	1040	100.0	ponA.l15.c4.ctg.2	1229	30.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	138	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1503	18.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	382	382	C	15	C	9	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	170	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1600	20.1	0	.	p	.	0	N38E	NONSYN	112	114	AAT	374	376	GAA	29;29;29	G;A;A	20;19;19	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	170	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1600	20.1	0	.	p	.	0	N134D	NONSYN	400	402	AAT	662	664	GAT	15;15;15	G;A;T	9;10;8	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	170	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1600	20.1	0	.	p	.	0	M141I	NONSYN	421	423	ATG	683	685	ATA	15;15;15	A;T;A	9;10;8	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	170	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1600	20.1	0	.	p	.	0	P175S	NONSYN	523	525	CCA	785	787	TCA	26;26;26	T;C;A	12;16;16	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	170	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1600	20.1	0	.	p	.	0	A218V	NONSYN	652	654	GCC	914	916	GTC	26;27;27	G;T;C	13;15;15	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	170	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1600	20.1	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1244	1246	GCA	33;33;31	G;C;A	21;20;20	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	170	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1600	20.1	1	SNP	p	G120K	1	.	.	358	360	AAG	620	622	AAG	15;15;15	A;A;G	10;11;11	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	170	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1600	20.1	1	SNP	p	A121D	1	.	.	361	363	GAC	623	625	GAC	15;15;15	G;A;C	10;10;11	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	170	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1600	20.1	1	SNP	p	D121N	0	.	.	361	363	GAC	623	625	GAC	15;15;15	G;A;C	10;10;11	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	628	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4560	27.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1837	1839	AAT	36;38;38	A;A;T	25;26;26	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	48	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	670	12.7	1	SNP	p	V57M	1	.	.	169	171	ATG	328	330	ATG	16;16;16	A;T;G	11;10;11	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
